Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Clin Transl Sci ; 17(8): e13899, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-39080841

RESUMO

Allergic disease prevalence has increased globally with the subset of type 2 inflammatory diseases playing a substantial role. Type 2 inflammatory diseases may differ in clinical presentation, but they exhibit shared pathophysiology that is targeted by the unique pharmacology of dupilumab. Dupilumab binds to the interleukin (IL)-4 receptor alpha subunit (IL-4Rα) that blocks IL-4 and IL-13 signaling, two key drivers of type 2 inflammation. Herein, we review the mechanism of action and pharmacology of dupilumab, and the clinical evidence that led to the regulatory approvals of dupilumab for the treatment of numerous type 2 inflammatory diseases: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.


Assuntos
Anticorpos Monoclonais Humanizados , Dermatite Atópica , Interleucina-13 , Subunidade alfa de Receptor de Interleucina-4 , Pesquisa Translacional Biomédica , Humanos , Anticorpos Monoclonais Humanizados/uso terapêutico , Anticorpos Monoclonais Humanizados/farmacologia , Subunidade alfa de Receptor de Interleucina-4/antagonistas & inibidores , Subunidade alfa de Receptor de Interleucina-4/metabolismo , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/imunologia , Interleucina-13/antagonistas & inibidores , Interleucina-13/metabolismo , Interleucina-13/imunologia , Interleucina-4/antagonistas & inibidores , Interleucina-4/metabolismo , Asma/tratamento farmacológico , Asma/imunologia , Esofagite Eosinofílica/tratamento farmacológico , Esofagite Eosinofílica/imunologia , Transdução de Sinais/efeitos dos fármacos , Pólipos Nasais/tratamento farmacológico , Pólipos Nasais/imunologia , Prurigo/tratamento farmacológico , Ciência Translacional Biomédica , Sinusite/tratamento farmacológico , Sinusite/imunologia
2.
Clin Transl Sci ; 17(4): e13762, 2024 04.
Artigo em Inglês | MEDLINE | ID: mdl-38591811

RESUMO

Mibavademab (previously known as REGN4461), a fully human monoclonal antibody, is being investigated for the treatment of conditions associated with leptin deficiency. Here, we report pharmacokinetics (PKs), pharmacodynamics, and immunogenicity from a phase I study in healthy participants (NCT03530514). In part A, lean or overweight healthy participants were randomized to single-ascending-dose cohorts of 0.3, 1.0, 3.0, 10, and 30 mg/kg intravenous (i.v.), or 300 and 600 mg subcutaneous doses of mibavademab or placebo. In part B, overweight or obese participants were randomized to receive multiple doses of mibavademab (15 mg/kg i.v. loading dose and 10 mg/kg i.v. at weeks 3, 6, and 9) or placebo, stratified by body mass index and baseline leptin levels: low leptin (<5 ng/mL) or relatively low leptin (5-8 ng/mL in men and 5-24 ng/mL in women). Fifty-six and 55 participants completed the single-ascending-dose and multiple-dose parts, respectively. In the single-ascending-dose cohorts, mibavademab PKs were nonlinear with target-mediated elimination, greater than dose-proportional increases in exposure, and there were no dose-dependent differences in total soluble leptin receptor (sLEPR) levels in serum over time. Following multiple-dose administration of mibavademab in participants with leptin <8 ng/mL, lower mean mibavademab concentrations, higher mean total sLEPR concentrations, and larger mean decreases in body weight than in the relatively low leptin cohorts were observed. Baseline leptin was correlated with mibavademab PKs and pharmacodynamics. No treatment-emergent anti-mibavademab antibodies were observed in any mibavademab-treated participant. Results from this study collectively inform further development of mibavademab to treat conditions associated with leptin deficiency.


Assuntos
Leptina , Sobrepeso , Masculino , Humanos , Feminino , Leptina/farmacocinética , Leptina/uso terapêutico , Receptores para Leptina/uso terapêutico , Obesidade/tratamento farmacológico , Índice de Massa Corporal , Método Duplo-Cego
3.
Clin Pharmacol Drug Dev ; 13(6): 621-630, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38323727

RESUMO

Osteoarthritis (OA) pain management options are currently limited. Fasinumab, an anti-nerve growth factor monoclonal antibody, has been investigated in healthy volunteers and patients with OA-related pain, among other conditions. Data from 12 Phase I-III clinical trials of 92 healthy volunteers and 7430 patients with OA were used to develop a population pharmacokinetic model to characterize fasinumab concentration-time profiles and assess the covariates' effect on fasinumab pharmacokinetic parameters. Participants received single or repeated fasinumab doses intravenously (IV)/subcutaneously (SC), based on body weight (0.03-1 mg/kg IV or 0.1-0.3 mg/kg SC)/fixed dose (9-12 mg IV or 1-12 mg SC). Fasinumab concentration-time data following IV and SC administration in healthy volunteers and patients with OA-related pain were adequately described by a 2-compartment model. Bioavailability increased with higher doses; estimated at 55.1% with 1 mg SC dose, increasing in a greater-than-proportional manner above this. Body weight had the largest predicted impact on fasinumab steady-state exposures, participants at the 5th and 95th percentiles had a 43%-45% higher/22%-23% lower exposure versus reference, respectively. Other covariates had small but clinically irrelevant impacts.


Assuntos
Anticorpos Monoclonais Humanizados , Voluntários Saudáveis , Osteoartrite do Quadril , Osteoartrite do Joelho , Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Adulto , Osteoartrite do Joelho/tratamento farmacológico , Osteoartrite do Joelho/complicações , Idoso , Osteoartrite do Quadril/tratamento farmacológico , Osteoartrite do Quadril/complicações , Anticorpos Monoclonais Humanizados/farmacocinética , Anticorpos Monoclonais Humanizados/administração & dosagem , Modelos Biológicos , Dor/tratamento farmacológico , Disponibilidade Biológica , Injeções Subcutâneas , Adulto Jovem , Relação Dose-Resposta a Droga , Ensaios Clínicos Fase III como Assunto
4.
Clin Transl Sci ; 17(8): e13874, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-39077906

RESUMO

Interleukin-33 (IL-33) is a proinflammatory alarmin cytokine released by damaged epithelial tissue cells that initiates and amplifies both type 1 and type 2 inflammatory cascades. A role for IL-33 in atopic dermatitis (AD; a chronic, relapsing type 2 inflammatory disease of the skin) has been proposed. Itepekimab is a novel human IgG4P monoclonal antibody against IL-33, currently in clinical development for chronic obstructive pulmonary disease (COPD). Two global phase II studies-a dose-ranging itepekimab monotherapy study (NCT03738423) and a proof-of-concept study of itepekimab alone and in combination with dupilumab (NCT03736967)-were conducted in patients with moderate-to-severe AD to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy; both studies were terminated following an interim analysis of the proof-of-concept study, which failed to demonstrate the efficacy of itepekimab. In these two studies, itepekimab exhibited linear and dose-proportional pharmacokinetics. Pharmacodynamics of total IL-33 indicated that itepekimab saturated binding to the target in serum at 300 mg q2w and q4w doses, and decreased blood eosinophil counts. Concentration-time profiles of itepekimab and total IL-33 were similar for itepekimab with or without dupilumab, and between East Asian and non-East Asian subgroups. Itepekimab was generally well tolerated, both alone and in combination with dupilumab. The lack of clinical efficacy for itepekimab observed in these studies suggests that IL-33 may not be a key pathogenic driver in moderate-to-severe AD.


Assuntos
Anticorpos Monoclonais Humanizados , Dermatite Atópica , Interleucina-33 , Humanos , Anticorpos Monoclonais Humanizados/farmacocinética , Anticorpos Monoclonais Humanizados/administração & dosagem , Anticorpos Monoclonais Humanizados/efeitos adversos , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/imunologia , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Resultado do Tratamento , Quimioterapia Combinada/métodos , Adulto Jovem , Estudo de Prova de Conceito , Relação Dose-Resposta a Droga , Idoso , Método Duplo-Cego
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa